A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
Background: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not b...
Saved in:
Published in | Journal of gynecologic oncology Vol. 33; no. 2; pp. 1 - 8 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | Korean |
Published |
대한부인종양학회
01.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi.
Methods: The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023. |
---|---|
AbstractList | Background: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi.
Methods: The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023. |
Author | Junsik Park Min Chul Choi Myong Cheol Lim Dae Hoon Jeong Jung-yun Lee Byoung-gie Kim Se Ik Kim Jae-kwan Lee |
Author_xml | – sequence: 2 fullname: Junsik Park – sequence: 3 – sequence: 4 fullname: Myong Cheol Lim – sequence: 5 fullname: Jae-kwan Lee – sequence: 6 fullname: Dae Hoon Jeong – sequence: 7 fullname: Se Ik Kim – sequence: 8 fullname: Min Chul Choi – sequence: 9 fullname: Byoung-gie Kim – sequence: 10 fullname: Jung-yun Lee |
BookMark | eNp9jM1Kw0AUhbOoYKs-gZu7VGhwSGht3QXRWAptKeK23KS3zdXkzjAzicSH7jM4imtX53B-vlE0EC00iIaJUpNYpTN1Ho2ce1dqeq9myTA6ZeBYjjXFaJsxmAodwWIBzrf7HvQBhC0atFwAyh4K6rDkr7bBAhpk8SQoJYGvKMx6YAFTo2dpm9iROPbc0Rgsla21JB50F1goUP7cLJiwDbEDY6lj3bq6B28JPe3hk30FCJtsuwncigv22j7AUodeIO-FSl3rI5ewll_XQ251a-Bmma9zSNVkenu3WmzfslUWbwOWsb6Mzg5YO7r604vo-vnp9fEl_mDndsZyg7bfpfM0Seez9P_2G-SscuA |
ContentType | Journal Article |
DBID | HZB Q5X |
DatabaseName | KISS(한국학술정보) Korean Studies Information Service System (KISS) B-Type |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial |
ExternalDocumentID | 3932398 |
GroupedDBID | 29K 2WC 5-W 53G 5GY 8JR 8XY 9ZL AAKDD ABDBF ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL D-I DIK DU5 E3Z EBD EF. F5P GROUPED_DOAJ HZB M~E OK1 Q5X RPM |
ID | FETCH-kiss_primary_39323983 |
ISSN | 2005-0380 |
IngestDate | Wed Aug 28 03:03:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | Korean |
LinkModel | OpenURL |
MergedId | FETCHMERGED-kiss_primary_39323983 |
Notes | Korean Society of Gynecologic Oncology |
PageCount | 8 |
ParticipantIDs | kiss_primary_3932398 |
PublicationCentury | 2000 |
PublicationDate | 20220301 |
PublicationDateYYYYMMDD | 2022-03-01 |
PublicationDate_xml | – month: 03 year: 2022 text: 20220301 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Journal of gynecologic oncology |
PublicationTitleAlternate | Journal of Gynecologic Oncology (JGO) |
PublicationYear | 2022 |
Publisher | 대한부인종양학회 |
Publisher_xml | – name: 대한부인종양학회 |
SSID | ssj0067082 ssib044744451 |
Score | 4.5310087 |
Snippet | Background: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for... |
SourceID | kiss |
SourceType | Publisher |
StartPage | 1 |
SubjectTerms | Bevacizumab Ovarian Neoplasms Poly(ADP-ribose) Polymerase Inhibitors Recurrence Retreatment |
Title | A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial |
URI | https://kiss.kstudy.com/ExternalLink/Ar?key=3932398 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lj9MwEICt7R4QFwQsCFhAcyASKBto3gm39EHbXbVbVQva2ypOXRq1Taq-UPdH8xuYcR6NRJGAi2VZ6VTyfLHHzjwYe-dMXMeNzEizhIWNFXKNG2MPm7ofipBbhoyF6Q-c7lfr8ta-PamxitfSdsM_RvdH40r-R6s4hnqlKNl_0GwpFAewj_rFFjWM7V_pOFDppD8XWriSal1OcU9Se70saaz00Yipwvkq5vIjARe7MIrvt4uQq4uQMkUkMmIgC8KSEYBL8o1LtgttTZ7ttBaS4BXdyss8TukOpeGaENEPV0Va1jXlGtiRO-18n_muF17toToMRkOUPI15TN8HzEC9Sld0_9_ZJyLK1l71OomyZFDZ5RiavVed645KJw_FoFylg97oWzAItJEq64z8wab-XhGZ5iJLHyGqhjJTh5XgpP6eKi01pyKdU6RX-WQotNkPqmcsSuxboVC7Kb4qlyLNN_v8rgSP2aWzmKRbaTcUr0kuJO2W4tuK36SRhiNHmorfUhoedQJD8Ww54ii-Xjzsy06AEg5rtEzkWjezYlTFhpJl9shfHKOyO-iHTbd0hTTRgDZ9r8Zqpm5XrgRwPbQs16L8cYVl4bh1Wfys_FM0I_CUsa4YRDeP2aN81iHIsHzCTmbpU_agn_tqnLGfARzovADJJvR6INmEdAIlm4BsQoVNqLAJOZsQJ_A7mxdQkgk5mZCRCQWZcCATcjKByIQQiEwoyfwMGZdQ4RIKLkFyCe-JSiAqP3wqiQRJ5DN2_qV90-xqNFd3yyyJy10-7-ZzdpqkiXjBYDx2PK5z37Uj14qMOncj2x_rk7ouIsszxUt2dkzCq-PD5-zhgcDX7HSz2oo3aL9u-Fup5F-4zqRs |
link.rule.ids | 315,786,790 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+single-arm%2C+phase+II+study+of+niraparib+and+bevacizumab+maintenance+therapy+in+platinum-sensitive%2C+recurrent+ovarian+cancer+patients+previously+treated+with+a+PARP+inhibitor%3A+Korean+Gynecologic+Oncology+Group+%28KGOG+3056%29%2FNIRVANA-R+trial&rft.jtitle=Journal+of+gynecologic+oncology&rft.au=Junsik+Park&rft.au=Myong+Cheol+Lim&rft.au=Jae-kwan+Lee&rft.au=Dae+Hoon+Jeong&rft.date=2022-03-01&rft.pub=%EB%8C%80%ED%95%9C%EB%B6%80%EC%9D%B8%EC%A2%85%EC%96%91%ED%95%99%ED%9A%8C&rft.issn=2005-0380&rft.volume=33&rft.issue=2&rft.spage=1&rft.externalDocID=3932398 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-0380&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-0380&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-0380&client=summon |